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Abstract Despite a marked improvement of in-hospital
outcome of patients with Acute Coronary Syndrome (ACS),
long-term outcome remains poor. There remains a high risk of
complications, Non ST-Elevation ACS (NSTE-ACS) patients
being at higher risk than those with ST-elevation ACS, in part
due to more diffuse coronary artery disease. Whether with
conservative medical management or an early invasive
approach, of which they less frequently benefit, NSTE-ACS
patients are less frequently treated according to guidelines.
Therapeutic adhesion within the months following hospital
discharge is low and associated with an increase in one-year
mortality. The next step in the improvement of care of ACS
patients will be to use multi-dimensional prevention programs
that use didactic information tools and improve patient
motivation, aimed at reinforcing the use of guidelines,
promoting in-hospital therapeutic education, creating patient-
health care provider partnerships and including discharge
programs that ensure the prescription of recommended
therapies.
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Introduction to the pathogenesis and treatment
strategies of acute coronary syndromes
Coronary artery disease is the result of the development of
coronary atherosclerosis. The pathogenesis is complex and
linked to the proliferation of smooth muscle cells, synthesis of
connective tissue matrix, focal accumulation of monocytes/
macrophages, infiltration of lymphocytes and various levels of
intracellular and extracellular lipid accumulation. Atheroscle-
rosis can be considered to be a response to injury, with the
major risk factors being elevated blood pressure, pathological
lipid profiles, cigarette smoking, diabetes mellitus, family
history, age and gender, some of these being modifiable.
Atherosclerosis is a chronic disease that can affect all arteries,
and in particular the cerebral, cardiac, renal and peripheral ones.
The clinical manifestations are a consequence of the subsequent
progressive or acute occlusion of these arteries and include
coronary heart disease, cerebrovascular disease and peripheral
arterial disease. With regard to cardiac manifestations, the
disease ranges from an asymptomatic state to potential sudden
death. Angina pectoris (chest pain) often presents in patients
who develop progressive obstruction of their coronary arteries,
referred to as stable coronary artery disease. Acute coronary
syndromes (ACS) cover the constellation of acute clinical
presentations linked to the rupture of an unstable atherosclerotic
plaque and the subsequent platelet aggregation and thrombus
formation that acutely and often completely occludes a
coronary artery. ACSs have been categorized using clinical,
elecrocardiographical and biological criteria. Thus clinical
presentations associating elevation of biomarkers of myocardial
injury with electrocardiographic ST segment elevation are
referred to as ST elevation myocardial infarction (MI)
(STEMI), those without ST elevation are referred to as Non
ST-elevation MI (NSTEMI or NSTE-ACS) and when the
syndrome is accompanied by neither STelevation or biomarker
elevation, it is referred to as Unstable Angina (UA). The overall
therapeutic aim in all circumstances is to reestablish coronary
patency and thus balance myocardial demand and supply of
oxygenated blood. Revascularization is primarily achieved using
percutaneous coronary interventions (PCI) and angioplasty in
association with powerful anti-thrombotic agents and subsequent
clinical and electrocardiographic monitoring. Secondary
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cardiovascular prevention is essential in the subsequent
management phase and requires patient and healthcare
provider education and the application of international
therapeutic guidelines to ultimately ensure patient
therapeutic adhesion.
Introduction
The prognosis of acute coronary syndrome (ACS) has
much improved in recent years as a result of advances in
the early initiation of anti-thrombotic therapies, early
invasive management and the development of coronary
care units. Nevertheless, the risk of recurrence of cardio-
vacular complications after an ACS remains as high as 15%
at 12 months [1]. International guidelines recommend
pharmacologic and lifestyle interventions to reduce recurrent
events in patients with coronary and other atherosclerotic
vascular disease. However, audits of practice reveal subopti-
mal control of cardiovascular risk factors and under use of
evidence-based cardiovascular medication [2]. Consequently
the lack of in-hospital initiation of evidence-based cardio-
vascular medications seems to alter long-term patient
compliance and clinical outcomes [3, 4]. In addition, 30%
of patients stop their treatment either partially or totally
within 30 days after hospital discharge with a significant
increase in 1-year mortality [5]. In the United States, projects
have tested pragmatic interventions targeting an increase in
prescription rates by physicians and/or long-term medication
adherence by patients [6–10]. In Europe, Wood et al.
recently showed an association between healthier lifestyle
and improvements in cardiovascular risk factor control for
patients with coronary heart disease who benefitted from a
nurse coordinated, multidisciplinary, family-based, ambula-
tory program [11]. The benefit of in-hospital multidimen-
sional interventions for patients after an ACS was
demonstrated in a recent review and meta-analysis [12]. In
this meta-analysis, secondary prevention programs were
categorized as patient-, health care provider- (HCP) and
system-level interventions [13]. It was demonstrated that
multidimensional interventions, targeting the patients, the
provider and the health care system increased prescription
rates of proven efficacious medication and seemed to reduce
mortality and recurrent ACS [12, 14]. Data from the
international GRACE registry showed various prescription
rates of cardiovascular medication according to regions of
the world [15]. Variations across countries might be due to
national quality improvement strategies and probably cultural
differences as well. To date, there is no systematic prospective
data collection in the setting of a nation-level multi-
dimensional quality improvement strategy or incentives to
improve the care of patients with coronary heart disease.Multi-
dimensional quality improvement programs should be imple-
mented to firstly improve the application of recommended
therapies for patients admitted to the hospital for an ACS,
secondly, to improve patient therapeutic education, and finally
to improve the continuation of education and recommended
medical management for long-term secondary prevention in a
health care system network including acute care hospitals,
rehabilitation centers and outpatient physicians.
ACS patients have a high risk of recurrent
cardiovascular events and of mortality
Overall mortality rates from the onstart of myocardial
injury before hospital admission until discharge is difficult
to determine because of several clinical and epidemiological
limitations such as the frequent occurrence of silent ischemia
or silent MI, the consistent rate of pre-hospital sudden death,
and the varying methods and definitions used in the diagnosis
of death and its etiology. Population studies have consistently
shown that overall case fatality rates of patients with presumed
MI or ACS in the first 30 days is higher than 50%, and about
half of these deaths occur within the first 2 h [16]. Pre-hospital
mortality seems to have modestly decreased over the last
decades in contrast with in-hospital mortality after an ACS,
which was markedly decreased thanks to monitoring in
coronary care units, improvement of in-hospital care including
urgent reperfusion using thrombolytic therapy and primary
percutaneous coronary intervention (PCI) in STEMI, new
anti-thrombotic therapies, the use of more sensitive
biomarkers of risk such as troponin, and a better stratification
of the predicted risk with an early invasive strategy for
intermediate and higher risk NST-ACS patients [17]. The
short-term mortality rate after an ACS is markedly higher for
patients with ST-elevation myocardial infarction (STEMI)
than for patients with non ST-elevation myocardial infarction
(NSTEMI) itself higher than that of patients with unstable
angina (UA) [18]. Nevertheless, Terkelsen et al. demonstrated
a similar favorable trend of mortality for patients admitted to
hospital for STEMI and NSTEMI between 1994 and 2006.
Indeed after hospital admission, hospital mortality of patients
admitted for MI (STEMI and NSTEMI) fell from 10.4% to
6.3%, and mortality of patients with STEMI fell from 11.5%
to 8.0%, and of patients with NSTEMI from 7.1% to 5.2%
(all P<0.0001). After adjustment for baseline characteristics,
hospital mortality fell among all patients by 23.6% (odds ratio
(OR) 0.764, 95% CI 0.744-0.785), STEMI by 24.2% (OR
0.758, 0.732-0.784), and NSTEMI by 22.6% (OR 0.774,
0.741-0.809), all P<0.001. Similarly a significant decrease of
mortality rate was also demonstrated between two time
periods: 2001–2002 and 2003–2004 for patients admitted
for NSTEMI and UA due to the implementation of more
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recent guidelines, which include more aggressive antithrom-
botic therapy associated with early invasive approaches or
coronary angiography and subsequent PCI [19, 20]. Of note
this study demonstrated the favorable impact of the imple-
mentation of new guidelines on the outcome of patients in the
setting of NSTE-ACS.
Paradoxically, long-term mortality rate is higher for
patients with non ST-elevation ACS (NSTE-ACS) than those
with STEMI as it was shown in the data published by
Terkelsen et al.: from hospital admission, 1 year mortality was
31% for NSTEMI patients, 21% for STEMI patients, and 55%
for MI associated with a bundle branch block (P<0.001)
(Fig. 1) [21]. Interestingly, one-month mortality has since
been reduced to a much lower level of 4-6% [22, 23] or even
less [24] in large-scale randomized trials compared to
registries suggesting that patients included in randomized
trials are at lower risk when compared with those observed
in the real world [25]. All these data demonstrate that in-
hospital and 30-day mortality has been markedly decreased
over the last decades due in part to improvements in medical
therapies and to more aggressive earlier invasive interven-
tions. Short-term mortality rate is higher in STEMI than in
NSTE-ACS, however this difference is already abolished
after 1 year and the decrease of one-year mortality rate over
the years is less pronounced than the decrease of 30-days
mortality rate. These data summarize the favorable impact of
in-hospital management of the acute phase of ACS and the
weaker impact of therapeutic progresses on long-term
outcome after an ACS. Long-term outcome of patients after
an ACS is mainly dependent on the chronic nature of
atherosclerosis, which exposes ACS patients to a high risk
(15%) of recurrent cardiovascular events at 1 year [1]. In the
past, restenosis was a reason for recurrent target lesion
revascularization after PCI in 20-30% after stenting proce-
dures without significant impact on mortality, however the
use of drug-eluting stents gave a definite solution to this
issue [26]. Recurrent cardiovascular events after an ACS are
therefore today mainly explained by the natural history of
atherosclerosis with plaque progression and rupture. Indeed
Cutlip et al. demonstrated even before the era of drug-eluting
stents that after 2 years, the rate of stable and unstable
recurrent coronary events occurred 5 times more frequently
in other coronary arteries than that involved during the initial
ACS [27].
In-hospital underuse of recommended therapies
after an ACS
Unfortunately, important gaps exist between international
recommendations for the management of patients with ACS
and atherosclerosis and everyday practice (Fig. 2) [28]. Of
note, if treatment in secondary prevention of atherosclerosis
after a MI is not initiated at the time of discharge, the
likelihood of ever receiving treatment is low. On the other
hand if medical therapy in secondary prevention after MI is
started early, most patients adhere to treatment on the long
term. Furthermore, the prescribed doses of medications are
usually and substantially lower than those recommended
and seldom adjusted during long-term therapy [29, 30].
Interestingly, patients admitted for an ACS treated medi-
cally are less likely to be treated according to guidelines
than those who benefit from an invasive management [31].
Therefore reinforcement of the application of guidelines
in ACS and secondary prevention must be implemented
to increase the rate of prescription of recommended
therapies during the hospital stay of patients admitted
for an ACS. Such programs have been successfully
implemented for example the Cardiac Hospitalization
Atherosclerosis Management Program (CHAMP), which was
developed and implemented at a university-affiliated
Fig. 1 Kaplan-Meier survival curves after STEMI, nonSTEMI and
BBBMI. With permission of Terkelsen et al. [21]. STEMI: ST-Elevation
Myocardial Infarction; nonSTEMI: non ST-Elevation Myocardial
Infarction; BBBMI: bundle Branch Block related Myocardial Infarction
% of recommended medical therapy at hospital discharge
STEMI  NSTEMI UA
Fig. 2 Prescription rate of recommended therapies at discharge
according with each category of acute coronary syndrome. According
with the data of Steg et al. [28]. STEMI : ST-Elevation Myocardial
Infarction; nonSTEMI: non ST-Elevation Myocardial Infarction; UA:
Unstable Angina
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teaching hospital [7]. The program focused on initiation of
aspirin, cholesterol-lowering medication titrated to achieve
the recommended target level of LDL-cholesterol, beta-
blocker, and angiotensin-converting enzyme (ACE) inhibitor
therapy in conjunction with lifestyle change counseling in
patients with established coronary artery disease before
hospital discharge. A clinical study assessed the impact of
the CHAMP program on secondary prevention medication
utilization in a before/after design including 256 and 302
patients respectively in each time period. Aspirin use at
discharge improved from 68% to 92% (p<0.01), beta-
blocker use improved from 12% to 62% (p<0.01), ACE
inhibitor use increased from 6% to 58% (p<0.01), and statin
use increased from 6% to 86% (p<0.01). This increased use
of treatment persisted during subsequent one-year follow-up.
There was also a significant increase in patients achieving
LDL cholesterol <100 mg/dl (6% vs 58%, p<0.001) and a
reduction in recurrent 1-year MI (7.8% vs 3.1%, p<0.05),
total mortality (7% vs 3.3%, p<0.05), and cardiac mortality
(5.1% vs 2%, p<0.05) [7].
The American College of Cardiology, in partnership with
the Michigan quality improvement organization and the
Greater Detroit Area Health Council, initiated the American
College of Cardiology’s Guidelines Applied in Practice (GAP)
in Michigan in 1999 to improve the quality of care after MI by
reinforcing the application of guidelines and by using standard
admission ordersets and standard discharge contracts associated
with strong physician and nurse administrative case manage-
ment controls [32, 33]. This pilot program included 2,857
patients admitted for MI (1,368 patients before and 1,489
patients after program implementation in a before/after design)
and showed a 21% to 26% reduction in mortality, particularly
at 30 days (odds ratio of GAP to baseline 0.74; 95% CI 0.59
to 0.94; p=0.012) and 1 year (odds ratio 0.78; 95% CI 0.64 to
0.95; p=0.013) [10]. In addition to such quality improvement
programs based on medical therapy, lifestyle change programs
initiated at hospital have also demonstrated significant impact
on outcomes after an ACS. In-hospital non-pharmacologic
and smoking cessation counseling interventions seemed to be
effective in a systematic review of randomized controlled
trials including patients with coronary artery diseases [34, 35].
Importantly, cardiac rehabilitation programs are an important
corner stone in the educational process of care after an ACS.
Indeed Taylor et al. [36] demonstrated in a meta-analysis
including 48 trials with a total of 8940 patients that phase 2
cardiac rehabilitation program reduced all-cause mortality by
20% (OR 0.80; 95% CI: 0.68 to 0.93) and cardiac mortality
by 26% (OR=0.74; 95% CI: 0.61 to 0.96). Therefore phase 2
cardiac rehabilitation is a class 1 recommendation according
to international guidelines [37]. Unfortunately and despite
these robust recommendations only 30% of patients after an
ACS benefit from a phase 2 cardiac rehabilitation program
[38]. Referring patients to cardiac rehabilitation centers is one
major intervention of the numerous interventions recommen-
ded for patients after an ACS. Of note cardiac rehabilitation
programs reinforce the use of recommended therapies and of
therapeutic education in secondary prevention.
Lack of medication adherence after an ACS
Therapeutic adherence rates to medication are typically higher
among patients with acute disease than those with chronic
illness. Furthermore, adherence rates among patients with
chronic conditions are disappointingly decreased over time,
dropping most dramatically after the first 6 months of therapy
[39–41]. For example, approximately half of elderly patients
receiving a statin therapy for dyslipidemia in primary and
secondary prevention will discontinue their medication
within 6 months after starting the medication [42].
Taking into account the definition of the International
Society for Pharmacoeconomics and Outcome Research,
medication compliance or medication adherence refers to
the act of conforming to the recommendations of medical
prescription with respect to timing, dosage, and frequency
of medication taking [40]. In summary medication adherence
is the extent to which a patient acts in accordance with the
prescribed dosing regiment. The unit of measure is admin-
istered doses per defined period of time, reported as the
proportion of prescribed doses taken in the prescribed time
interval (%) (Fig. 3). Medication persistence is defined as
“the duration of time from initiation to discontinuation of
therapy”, independently of the regiment dose or frequency of
the medication (Fig. 3) [40].
Noncompliant behavior is a critical issue in the care of
patients with chronic disease. Noncompliant behavior is a
consequence of several parameters (Table 1) and especially
of a physician-patient alliance failure. The impact of the
lack of therapeutic adhesion was noted in observational
studies [5] and also noticed in controlled randomized trials
Medication adherence
Medication Persistence
% of dose taken as prescribed
Days taking medication









Fig. 3 Definitions of medication adherence and persistence proposed
by the Issues and Methods Definitions Working Group of the
Medication Compliance and Persistence Special Interest Group.
According with the publication of Cramer et al. [40]
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showing average adherence rates of only 43-78% among
patients receiving medication for chronic diseases [53].
Importantly, patients included in randomized trials benefit
from a close monitoring of medication following the quality
and safety control of such studies and this should be in
favor of more favorable therapeutic adhesion rates. In the
modern era, there have been major changes in physician-
patient interaction and agreement. The traditional authoritarian
approach of the caregiver has evolved towards a collaborative
partnership with the patient in order to jointly define the
modalities of the medical management of health, disease and
preventive medical and lifestyle interventions. Noncompliant
behavior is most often the result of a communication failure
consecutive to lack of consideration of several important
psychosocial dimensions of individuals facing chronic disease.
These psychosocial dimensions include the self-representation
of illness and the benefit of its medical management, the belief
of such a benefit, the confidence in medical management and
in the caregiver, and finally in the motivation to change daily
habits by taking long-term medication and by changing
lifestyle, which implies important behavior changes. Therefore
these changes have to be discussed with the patient and the
discussion needs to be interactive with a common objective of
patient-caregiver partnership instead of a simple recommen-
dation of treatment. The result should be that the patient
himself decides on the long-term medical management of his
chronic disease. Therapeutic education of the patient and
motivational interviewing has been developed to help patients
and caregivers to change and evolve towards a collaborative
partnership, which consists of care centered on the patient. A
widely used current model in therapeutic education of the
patient is that of shared decision making, in which physician
and patient discuss, negotiate and finally agree on the medical
condition and on problem solving.
The future for patients admitted to the hospital
with an ACS: use of multi-dimensional secondary
prevention programs
As a result of the benefit and safety of an early invasive
strategy in the care of patients with high risk ACS and
thanks to a trans-radial PCI approach, the duration of
hospital stay has decreased dramatically during the last
decade. Indeed even after administration of an intensive
anti-thrombotic therapy including glycoprotein IIb-IIIa
(GPIIbIIIa) receptor inhibitors, a same-day home discharge
after PCI via trans-radial approach has been demonstrated
to be safe and with a markedly favorable economic impact
in part due to the marked reduction in bleeding complica-
tions [54, 55]. Therefore the future of Diagnostic-Related
Group (DRG) reimbursement for patients admitted to
hospital for an ACS will be based on recommended
international guidelines [37], which recommend at least
24 h of hospitalization after PCI of the culprit lesion and
also be based on the more recent data about same-day
safety discharge after PCI under GPIIbIIIa receptor inhib-
itors [54]. Consequently hospital stay will shorten in the
future. This will reduce the time period for the educational
process of patients and might decrease its quality in the
actual context of suboptimal care of patients with an ACS
as it has been described above.
The future challenges in the care of patients with ACS
will be to sensitize physicians about the high long-term risk
Table 1 Predictors of noncompliant behavior according with illness and care-related predictors as well as patient related predictors with their
corresponding references
Predictors of noncompliant behavior for the management of chronic diseases References
Illness and care-related predictors
• Complexity of treatment [43]
• Inadequate follow-up or discharge planning [44, 45]
• Treatment of asymptomatic disease [44]
• Side effects of medication [46]
• Poor provider–patient relationship [45, 47]
• Patient’s lack of belief in benefit of treatment [45, 47]
• Presence of barriers to care or medications [46, 48]
• Cost of medication, unsufficient reimbursement, or both [49, 50]
• Missed appointments [46, 51]
Patient-related predictors
• Presence of cognitive impairment or psychological problems
such as depression
[43, 46, 47, 52]
• Patient’s misinterpretation or lack of insight into the illness [45, 48]
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of all patients having suffered from an ACS, to improve the
quality of care by increasing the rate of recommended
prescriptions according to guidelines, to improve in-hospital
education of care caregivers in the acute and long-term
treatments of patients with an ACS, to improve in-hospital
education of the patient and finally to improve communication
between hospitals, outpatient physician practices and cardiac
rehabilitation centers. These challenges will be of primary
importance in the future of hospital cost reimbursement.
The first essential step to achieve this complex objective in
quality improvement for patients with an ACS will be to
sensitize caregivers, including cardiologists, of the real risk of
ACS patients and to measure local practice of care for these
patients. Similarly to the recommended multidisciplinary
work-up necessary to perform primary PCI in tertiary hospitals
[56], a local inventory of practice and outcome should first be
planned. After the assessment of this local analysis of care
and outcome of patients with an ACS, a multidisciplinary
improvement program should be developed including all
caregivers from nurses, internists, cardiologists (non-invasive
and invasive), specialists in therapeutic education, nurses
assistants, and physiotherapists. The program should answer
the critical issues discussed above about the gap between an
ideal situation and the reality of care of patients with an ACS.
To achieve this objective, we have developed a multi-
dimensional prevention program after an Acute Coronary
Syndrome (ELIPS). The ELIPS program has been deployed
in all university hospitals in Switzerland, under the direction
of the Geneva University Hospitals.
The ELIPS program aims at improving the acute care of
patients with an ACS and long-term secondary prevention
of atherosclerosis by using a multi-dimensional or multi-
level approach. First of all, a reinforcement of guidelines
has been implemented at the caregivers-level and associated
with a discharge program of care to ensure the use of the
recommended therapies and lifestyle recommendation
(patient-level intervention). This discharge program was
designed based on the GAP program [33]. This program
includes a discharge card which is given to the patient and
allows for discussion with his family physician as well as
his cardiologist (system-level intervention). In addition,
information sessions have been given throughout the
Table 2 Summary of components of the ELIPS® program
Tools Components Providers Time of application
Educational program Motivational interviews or brief
motivational interventions
Medical staff of all hospitals
involved in the care of patients
with coronary artery disease:
CCU, Cathlab, Cardiology
division, cardiac rehabilitation
From the admission until







Film (DVD) The history of a patient admitted
with an ACS: the acute phase
and the need of secondary
prevention of a chronic disease
- Diffusion: hospital including
CCU, Cardiology division
and/or cardiac rehabilitation.
According to the demand of
the patient
- Distribution: family doctor
or cardiologist (campaign
of distribution)
Interactive wallchart Information about cardiovascular risk
factors, lifestyle counselling and
questions, self-assessment of
cardiovascular risk factors
Shown in the cardiology
division and in the cardiac
rehabilitation center
After the discharge of the ICU









- Information about cardiovascular
risk factors, lifestyle counseling
and questions, self-assessment
of cardiovascular risk factors.
- Hospital medical staff In and out of the hospital
- E-learning in motivational




CCU coronary care unit
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country to inform caregivers of referring hospitals and
outpatient physicians of the implementation of the overall
ELIPS program. Secondly, an educational process has been
developed taking into account the time limitation due to the
briefness of hospital stay in the setting of ACS and also the
limited resources for education of acute patients in public
hospitals. Because of these limitations, the most suitable
educational approach in the setting of ACS was motivational
interviewing. We therefore developed a program of motiva-
tional interviewing including an e-learning (www.elips-e-
learning.org) and a face-to-face training course dedicated to
nurses and in-hospital physicians (care-givers-level interven-
tion). Finally numerous and novel ACS and atherosclerosis
information tools were created in a uniform and comple-
mentary manner, dedicated to patients and healthcare
providers (patient-level intervention as well as healthcare-
providers-level intervention). These information tools include
a DVD film, a website (www.elips.ch), a smartphone
application, flyers, and an interactive wallchart for hospital
and rehabilitation center use (Table 2). All tools including
the motivational interviewing e-learning were translated into
the main spoken languages in Switzerland, namely English,
German, French and Italian. Moreover, the tools were
validated in all languages by all Swiss university hospitals,
by a university legal department and by a patient represen-
tative commission of validation.
A clinical study is ongoing to assess the efficacy of the
ELIPS program (Clinicaltrial.gov: NCT01075867) supported
by the Swiss National Science Foundation in a global
translational research project of ACS (www.spum-acs.ch). In
the context of this quality improvement program, including a
media campaign and a training process with potential
“contamination”, the evaluation study has a before-after
design. One thousand two hundred control patients were
included between 2009 and the deployment of ELIPS in
November 2010 and the same number of patients will be
included in the post-implementation phase. The results of the
study are expected for 2013. The primary endpoint will be the
recurrence of cardiovascular events (cardiovascular death,
non-fatal myocardial infarction, cerebrovascular attack, tran-
sient cerebral ischemic accident and lower limb ischemia) at
1 year. Events and endpoints will be assessed by an
independent adjudication committee. Numerous sub-studies
will assess the impact of the program on therapeutic adhesion,
the effect of a tobacco cessation program, and the effect on
quality of life and numerous biological markers.
Conclusions
Despite the marked improvement of the in-hospital outcome of
patients admitted for ACS due to improved electrocardio-
graphic monitoring, early invasive management and newer
anti-thrombotic therapies, long-term outcome of these patients
remains relatively poor, especially for NSTE-ACS as com-
pared to STEMI. The poorer outcome of NSTE-ACS
compared with STEMI patients is due to the different
characteristics of these two populations with a higher rate of
diffuse coronary disease in patients with NSTE-ACS, who are
often older and who present more comorbidities such as
diabetes and renal failure. Despite these differences in long-
term outcomes, physicians often consider NSTE-ACS as a
“smaller MI” than STEMI because of the better short-term in-
hospital outcome and these patients are less frequently referred
for coronary angiography and subsequent PCI [21]. Further-
more, the medical management for secondary prevention of
ACS patients who do not benefit from an invasive approach
is less frequently in accordance with recommendations than
their invasively treated counterparts [31]. Of note, audits have
demonstrated a gap between the ideal management of patients
admitted to hospitals with an ACS and the actual received
treatment and this is a major concern when aiming to
improve the outcome of these patients [28]. In addition to
the insufficient application of the recommended therapies by
physicians, there is an important gap between medical
prescription and patient therapeutic adhesion; this also has a
significant impact on outcome including mortality. Following
these observations, numerous quality improvement programs
have been developed, which will be of importance consider-
ing the future projected reduction in hospital stay duration
after an ACS. The latter is linked to progress in the acute care
of ACS including early invasive approaches and the radial
artery access for PCI with subsequent decrease of bleeding
[12, 54, 55]. The results of the assessment of the ELIPS
nation wide multi-dimensional quality improvement program
for patients admitted to the hospital for an ACS are expected
in 2013.
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